Edition:
United Kingdom

XOMA Corp (XOMA.OQ)

XOMA.OQ on NASDAQ Stock Exchange Global Market

31.88USD
15 Dec 2017
Change (% chg)

$0.29 (+0.92%)
Prev Close
$31.59
Open
$31.77
Day's High
$32.47
Day's Low
$30.71
Volume
62,437
Avg. Vol
64,974
52-wk High
$34.31
52-wk Low
$3.99

Chart for

About

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA... (more)

Overall

Beta: 3.07
Market Cap(Mil.): $161.31
Shares Outstanding(Mil.): 7.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.

* XOMA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT FOR XOMA 358 WITH REZOLUTE, INC.

07 Dec 2017

BRIEF-Xoma posts Q3 revenue of $36.2 million

* Qtrly diluted net income per share available to common stockholders $1.98 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

06 Nov 2017

BRIEF-XOMA ANNOUNCES MULTIPLE NEW LICENSE AGREEMENTS FOR PROPRIETARY PHAGE DISPLAY LIBRARIES

* XOMA ANNOUNCES MULTIPLE NEW LICENSE AGREEMENTS FOR PROPRIETARY PHAGE DISPLAY LIBRARIES

04 Oct 2017

BRIEF-XOMA Earns $3 million milestone payment from its license agreement with Nanotherapeutics

* XOMA earns $3 million milestone payment from its license agreement with nanotherapeutics Source text for Eikon: Further company coverage: [XOMA.O ]

11 Sep 2017

BRIEF-Novartis Pharma reports a 6.6 percent passive stake in Xoma Corp as of August 24, 2017

* Novartis Pharma AG reports a 6.6 percent passive stake in Xoma Corp as of august 24, 2017 - SEC filing‍​ Source text for Eikon: (http://bit.ly/2gEet2Y) Further company coverage:

05 Sep 2017

BRIEF-Xoma announces transformational license agreements for gevokizumab and its IL-1 beta intellectual property portfolio

* Xoma announces transformational license agreements for gevokizumab and its IL-1 beta intellectual property portfolio

25 Aug 2017

Competitors

  Price Chg
Albireo Pharma Inc (ALBO.OQ) $24.11 +0.65

Earnings vs. Estimates